Home Cart Sign in  
Chemical Structure| 548-04-9 Chemical Structure| 548-04-9

Structure of Hypericin
CAS No.: 548-04-9

Chemical Structure| 548-04-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Hypericin, a natural product isolated and purified from the herb of Hypericum perforatum L., is a photosensitive antiviral with anticancer and antidepressant agent derived from Hypericum perforatum.

Synonyms: NSC 407313; NSC 622946; SGX301

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Hypericin

CAS No. :548-04-9
Formula : C30H16O8
M.W : 504.44
SMILES Code : O=C1C2=C(O)C=C(O)C3=C2C4=C(C5=C6C(O)=CC(C)=C5C7=C4C1=C(O)C=C7C)C8=C3C(O)=CC(O)=C8C6=O
Synonyms :
NSC 407313; NSC 622946; SGX301
MDL No. :MFCD00016683
InChI Key :YDOIFHVUBCIUHF-UHFFFAOYSA-N
Pubchem ID :3663

Safety of Hypericin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H317
Precautionary Statements:P280-P301+P312+P330

Related Pathways of Hypericin

epigenetics
DNA

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Methicillin-resistant Staphylococcus aureus (MRSA) strain JE2 64 mg/L 24 hours To investigate the effect of hypericin on the minimum inhibitory concentrations (MICs) of β-lactam antibiotics (e.g., oxacillin, cefazolin, and nafcillin), showing that hypericin significantly decreased the MICs of these antibiotics. Acta Pharm Sin B. 2019 Nov;9(6):1174-1182
Vero E6 cells 3, 30, 300 nM 15 minutes under light or dark conditions To evaluate the antiviral efficacy of Hypericin against SARS-CoV-2. Results showed that under light conditions, 30 and 300 nM Hypericin significantly reduced viral titer (TCID50/mL from 105.5 to <101); under dark conditions, 300 nM Hypericin also significantly reduced viral titer (from 105.5 to 102.5). ACS Appl Mater Interfaces. 2022 Mar 30;14(12):14025-14032
INS-1 cells 20 nM, 200 nM, 2000 nM 72 hours To investigate the protective effect of Hypericin on INS-1 cell viability under high-glucose conditions. Results showed that Hypericin significantly improved INS-1 cell viability under high-glucose conditions, inhibited high-glucose-induced apoptosis and NO production. Int J Biol Sci. 2019 Jun 2;15(7):1472-1487
HepG2 cells 50-500 nM 2 hours To evaluate the transfection efficiency of photochemical internalization (PCI) technology in HepG2 cells. Results showed that transfection efficiency was significantly enhanced at 600 mJ/cm² radiant exposure, with a 60-75 fold increase compared to nonirradiated cells. ACS Appl Mater Interfaces. 2024 Aug 21;16(33):43416-43429

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Alcoholic liver injury model Gavage 168.50 mg/g Once daily for 8 weeks Hyperoside prevents alcoholic liver injury through antioxidation, with effects equivalent to silymarin Antioxidants (Basel). 2019 Oct 31;8(11):524
CD1 male mice MRSA bacteremia model Intravenous (hypericin), Intramuscular (oxacillin) 5 mg/kg Once daily (hypericin), Three times a day (oxacillin), for 3 days To evaluate the therapeutic effect of hypericin in combination with oxacillin in the MRSA bacteremia model, showing that the combination significantly reduced MRSA densities in target tissues. Acta Pharm Sin B. 2019 Nov;9(6):1174-1182
C57BL/6J mice HFHS-induced type II diabetes model Intraperitoneal injection 0.5 mg/kg, 1 mg/kg, 2 mg/kg Administered every other day for four months (prevention group) or 30 days (treatment group) To investigate the preventive and therapeutic effects of Hypericin on HFHS-induced type II diabetes in mice. Results showed that Hypericin significantly reduced fasting blood glucose levels, improved glucose intolerance and insulin intolerance, decreased islet β-cell apoptosis, and enhanced the anti-oxidative ability of pancreatic tissue. Int J Biol Sci. 2019 Jun 2;15(7):1472-1487

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01726764 Type 2 Diabetes ... More >> Depression Less << Phase 1 Completed - Denmark ... More >> Department of Clinical Pharmacology, Institute of Public Health, University of Southern Denmark Odense, Denmark, DK-5000 Less <<
NCT02862236 Subclinical Anxious Adults ... More >> Nootropic Potential of Hypericum and Alprazolam Healthy Adults Less << Phase 4 Completed - Israel ... More >> Technion, Israel Institute of Technology Haifa, Israel Less <<
NCT00000792 HIV Infections PHASE1 COMPLETED 1995-01-01 Johns Hopkins Adult AIDS CRS, ... More >>Baltimore, Maryland, 21287, United States|Beth Israel Deaconess - East Campus A0102 CRS, Boston, Massachusetts, 02215, United States|NY Univ. HIV/AIDS CRS, New York, New York, 10016, United States Less <<
NCT01921881 Type 2 Diabetes Phase 1 Completed - Denmark ... More >> Department of Clinical Pharmacology, Institute of Public Health, University of Southern Denmark Odense C, Denmark, DK-5000 Less <<
NCT02840331 Peritoneal Carcinomatosis Phase 3 Recruiting July 2020 Germany ... More >> University Department of General, Visceral and Transplant Surgery Recruiting Tübingen, Baden.Württemberg, Germany, 72076 Contact: Stefan Beckert, Prof. Dr.    +49-(0)7071-29-86619    stefan.beckert@med.uni-tuebingen.de    Contact: Alfred Königsrainer, Prof. Dr.    +49-(0)7071-29-86619    alfred.koenigsrainer@med.uni-tuebingen.de Less <<
NCT02448381 Cutaneous T-Cell Lymphoma Phase 3 Recruiting - -
NCT00000645 HIV Infections PHASE1 COMPLETED 1994-10-01 Beth Israel Deaconess - East C... More >>ampus A0102 CRS, Boston, Massachusetts, 02215, United States|University of Minnesota, ACTU, Minneapolis, Minnesota, United States|NY Univ. HIV/AIDS CRS, New York, New York, 10016, United States Less <<
NCT05380635 Cutaneous T-Cell Lymphoma/Myco... More >>sis Fungoides Less << PHASE2 COMPLETED 2022-08-16 Rochester Skin Lymphoma Medica... More >>l Group, Fairport, New York, 14450, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.98mL

0.40mL

0.20mL

9.91mL

1.98mL

0.99mL

19.82mL

3.96mL

1.98mL

References

 

Historical Records

Categories